{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:11:44Z","timestamp":1790223104336,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jconrel.2024.07.015","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T17:30:11Z","timestamp":1720719011000},"page":"38-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Therapeutic liposomal combination to enhance chemotherapy response and immune activation of tumor microenvironment"],"prefix":"10.1016","volume":"373","author":[{"given":"Zili","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candido G.","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis J.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry","family":"Ossendorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Snaar-Jagalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.07.015_bb0005","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/1078-0432.CCR-18-1851","article-title":"The immunoscore: colon cancer and beyond a C","volume":"26","author":"Angell","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0010","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1200\/JCO.2014.60.0213","article-title":"Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients","volume":"33","author":"Dienstmann","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0015","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdx030","article-title":"Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy","volume":"28","author":"Auclin","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0020","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1200\/JCO.20.01600","article-title":"Microsatellite instability in patients with stage III Colon cancer receiving fluoropyrimidine with or without Oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials","volume":"39","author":"Cohen","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0025","author":"Andr\u00e9"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0030","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer","volume":"29","author":"Haller","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2020.11.007","article-title":"Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II\/III colon cancer (CCOG-1302 study)","volume":"144","author":"Nakayama","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.addr.2015.10.022","article-title":"Recent advances of cocktail chemotherapy by combination drug delivery systems","volume":"98","author":"Hu","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0045","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.3748\/wjg.v22.i30.6876","article-title":"Mechanisms of drug resistance in colon cancer and its therapeutic strategies","volume":"22","author":"Hu","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0050","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0055","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0060","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101481","article-title":"The role of dendritic cells in cancer and anti-tumor immunity","volume":"52","author":"Marciscano","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0070","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.immuni.2022.04.016","article-title":"Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing","volume":"55","author":"MacNabb","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0080","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/ange.201804882","article-title":"Nanoparticle-mediated immunogenic cell death enables and potentiates Cancer immunotherapy","volume":"131","author":"Duan","year":"2019","journal-title":"Angew. Chem."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106556","article-title":"Induction of immunogenic cell death by novel platinum-based anticancer agents","volume":"187","author":"Chang","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0090","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/gut.2010.211722","article-title":"Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice","volume":"60","author":"Gonzalez-Aparicio","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0095","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/cas.13305","article-title":"Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model","volume":"108","author":"Shimizu","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-29363-9","article-title":"Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model","volume":"13","author":"Alimohammadi","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0105","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jconrel.2023.04.011","article-title":"Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation","volume":"357","author":"Gu","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0110","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003831","article-title":"Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study","volume":"10","author":"Xia","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1033483","article-title":"Understanding the role of toll-like receptors in lung cancer immunity and immunotherapy","volume":"13","author":"Hoden","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0125","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1002\/med.21480","article-title":"Basic understanding and therapeutic approaches to target toll-like receptors in cancerous microenvironment and metastasis","volume":"38","author":"Attar","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1049340","article-title":"Toll-like receptor-targeted anti-tumor therapies: advances and challenges","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2022.102172","article-title":"Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics","volume":"70","author":"Kaur","year":"2022","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0140","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41423-021-00780-y","article-title":"Impact of intracellular innate immune receptors on immunometabolism","volume":"19","author":"Chou","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202100166","article-title":"Synergistic activation of antitumor immunity by a particulate therapeutic vaccine","volume":"8","author":"Mai","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0150","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1182\/blood-2010-11-317966","article-title":"Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7\/8 ligands together enhances generation of CD8+ T cells retaining CD28","volume":"117","author":"Pufnock","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0155","doi-asserted-by":"crossref","first-page":"7826","DOI":"10.7150\/thno.37216","article-title":"Nanoparticle delivery of immunostimulatory agents for cancer immunotherapy","volume":"9","author":"Zhuang","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0160","doi-asserted-by":"crossref","first-page":"27252","DOI":"10.18632\/oncotarget.4583","article-title":"TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression","volume":"6","author":"Ho","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0165","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1016\/j.apsb.2021.03.014","article-title":"Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response","volume":"11","author":"Du","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0170","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1535-7163.MCT-16-0454","article-title":"The TLR3 agonist inhibit drug efflux and sequentially consolidates low-dose cisplatin-based chemoimmunotherapy while reducing side effects","volume":"16","author":"Ding","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0175","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0180","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-21-0888","article-title":"Early tumor\u2013immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer","volume":"12","author":"Kim","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0185","first-page":"822","article-title":"Metabolic regulation of macrophage polarization in cancer, trends","volume":"5","author":"Mehla","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0195","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-019-0568-z","article-title":"Tumor-associated macrophages: an accomplice in solid tumor progression","volume":"26","author":"Chen","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0200","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2019.10.020","article-title":"TLR 7\/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages","volume":"469","author":"Liu","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101202","article-title":"Macrophage polarization synergizes with oxaliplatin in lung cancer immunotherapy via enhanced tumor cell phagocytosis","volume":"14","author":"Li","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12111054","article-title":"Liposome-based drug delivery systems in cancer immunotherapy","volume":"12","author":"Gu","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0215","doi-asserted-by":"crossref","DOI":"10.1186\/s13104-017-2380-8","article-title":"Attachment of class B CpG ODN onto DOTAP\/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice","volume":"10","author":"Tada","year":"2017","journal-title":"BMC. Res. Notes"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0220","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nmeth.2888","article-title":"Non-invasive intravital imaging of cellular differentiation with a bright red-excitable fluorescent protein","volume":"11","author":"Chu","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0225","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/2326-6066.CIR-16-0283","article-title":"Efficient eradication of established tumors in mice with cationic liposome-based synthetic long-peptide vaccines","volume":"5","author":"Varypataki","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0230","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1208\/s12248-014-9686-4","article-title":"Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined Adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity","volume":"17","author":"Varypataki","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0235","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jconrel.2022.11.049","article-title":"Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer","volume":"353","author":"Gu","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.colsurfb.2009.03.019","article-title":"Effect of saturation degree on the interactions between fatty acids and phosphatidylcholines in binary and ternary Langmuir monolayers","volume":"72","author":"Hac-Wydro","year":"2009","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21249559","article-title":"Building blocks to design liposomal delivery systems","volume":"21","author":"Juszkiewicz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0250","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1039\/c1nr10166h","article-title":"The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses","volume":"3","author":"Ma","year":"2011","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0255","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/09687860600790537","article-title":"Immunostimulation of dendritic cells by cationic liposomes","volume":"23","author":"Vangasseri","year":"2006","journal-title":"Mol. Membr. Biol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114238","article-title":"Why nanoparticles prefer liver macrophage cell uptake in vivo","volume":"185","author":"Ngo","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0265","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1083\/jcb.40.1.216","article-title":"Measurement of rates of phagocytosis: the use of cellular monolayers","volume":"40","author":"Michell","year":"1969","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0270","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0275","article-title":"Combinatorial strategies for the induction of immunogenic cell death","volume":"6","author":"Bezu","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0280","unstructured":"F. Pentimalli, S. Grelli, N. Di Daniele, G. Melino, I. Amelio, Cell Death Pathologies: Targeting Death Pathways and the Immune System for Cancer Therapy, n.d. http:\/\/www.nature.com\/authors\/editorial_policies\/license.html#terms."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0285","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0290","author":"Basu","year":"2001"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0295","series-title":"Morphological Observations on the Fate of Liposomes in the Regional Lymph Nodes after Footpad Injection into Rats","author":"Velinova","year":"1996"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0300","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00262-011-0970-1","article-title":"Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine","volume":"60","author":"Vasievich","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0305","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0145-305X(03)00103-4","article-title":"Development and maturation of the immune system in zebrafish, Danio rerio: a gene expression profiling, in situ hybridization and immunological study","volume":"28","author":"Lam","year":"2004","journal-title":"Dev. Comp. Immunol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0310","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/(SICI)1097-0177(199904)214:4<323::AID-AJA5>3.0.CO;2-3","article-title":"Early hematopoiesis and developing lymphoid organs in the zebrafish","volume":"214","author":"Willett","year":"1999","journal-title":"Dev. Dyn."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0315","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt1169","article-title":"Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression","volume":"24","author":"Siew","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0320","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.7150\/thno.34429","article-title":"Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles","volume":"9","author":"Da Silva","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119417","article-title":"Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccines","volume":"220","author":"Da Silva","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.07.015_bb0330","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0335","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-023-02999-3","article-title":"Macrophage\u2019s role in solid tumors: two edges of a sword","volume":"23","author":"Jahandideh","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0340","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathmechdis-032221-115501","article-title":"Innate immunity and Cancer pathophysiology","volume":"17","author":"Maiorino","year":"2021","journal-title":"Annu. Rev. Pathol.: Mech. Dis."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1039260","article-title":"The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy","volume":"13","author":"Lu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.07.015_bb0350","doi-asserted-by":"crossref","DOI":"10.1023\/A:1020558317162","article-title":"Dendritic cells: a link between innate and adaptive immunity","volume":"19","author":"Palucka","year":"1999","journal-title":"J. Clin. Immunol."},{"issue":"2013","key":"10.1016\/j.jconrel.2024.07.015_bb0355","first-page":"286","article-title":"Neutralizing tumor-promoting chronic inflammation: a magic bullet?","volume":"339","author":"Coussens","year":"1979","journal-title":"Science"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924004462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924004462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T20:53:31Z","timestamp":1725742411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924004462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":71,"alternative-id":["S0168365924004462"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.015","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic liposomal combination to enhance chemotherapy response and immune activation of tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}